
    
      This is a randomized, parallel-group, double-blind, placebo controlled multicenter study to
      evaluate the safety and efficacy of CTP-656 in CF patients with CFTR gating mutations,
      compared to Kalydeco, for a total of 28 days. Subjects will be randomized to receive either
      double-blind CTP-656 or placebo, or open-label Kalydeco.
    
  